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Zika virus (ZIKV) constitutes an increasing public health
problem. Previous studies have shown that CD8+ T cells
play an important role in ZIKV-specific protective im-
munity. We have previously defined antigenic targets of
the ZIKV-specific CD8+ T cell response in humans. In
this study, we characterized the quality and phenotypes of
these responses by a combined use of flow cytometry and
transcriptomic methods, using PBMCs from donors de-
riving from different geographical locations collected in
the convalescent phase of infection. We show that ZIKV-
specific CD8+ T cells are characterized by a polyfunc-
tional IFN-g signature with upregulation of TNF-a,
TNF receptors, and related activation markers, such as
CD69, as well as a cytotoxic signature characterized by
strong upregulation of GZMB and CRTAM. The signa-
ture is stable and not influenced by previous dengue virus
exposure, geographical location, or time of sample collec-
tion postinfection. To our knowledge, this work eluci-
dates the first in-depth characterization of human CD8+
T cells responding to ZIKV infection. The Journal
of Immunology, 2018, 201: 3487–3491.
T
he relatively recent spread of Zika virus (ZIKV) in the
absence of any available treatment or preventative
vaccine has illustrated the need to better understand a
number of issues associated with this previously understudied
virus ranging from epidemiology, disease pathogenesis, and
host immune responses. CD8+ T cell immune responses seem
to play an important role in ZIKV-specific protective
immunity, contributing to protective immunity against
ZIKV. Dengue virus (DENV)–pre-exposed CD8+ T cells
are also able to mount cross-protective responses against
ZIKV challenge (1, 2). In this context, it is important to
study and define the features of ZIKV-specific CD8+ T cell
responses and ascertain whether these responses are fully
functional or somehow altered (especially in DENV–pre-
exposed donors), raising the possibility that these re-
sponses may be associated with immunopathology. We
previously showed that subjects characterized by prior
DENV infection displayed not only increased magnitude
of ZIKV responses in the acute phase but also showed a
skewed immunodominance pattern of responses toward
nonstructural proteins as previously observed in the con-
text of DENV infection (3, 4). However, an in-depth
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characterization of the functionality of ZIKV-specific
CD8+ T cell responses is not available to date.
Materials and Methods
Human blood samples and ZIKV and DENV determination
Blood donations from convalescent donors previously infected with ZIKVwere
collected (4) in Puerto Rico within the Recipient Epidemiology and Donor
Evaluation Study-III or at the University of North Carolina (UNC Institu-
tional Review Board no. 08-0895) and University of Miami from United
States travelers with Zika symptoms. An additional cohort was identified at
the Universidad del Norte in Barranquilla, Colombia. ZIKV infection was
confirmed using RT-PCR during the early acute/symptomatic phase (5).
Clinical and serological characteristics are summarized in Supplemental
Table I. In addition to positive RT-PCR, previous ZIKV infections in con-
valescent phase samples were also confirmed using ZIKV neutralization assays,
depleting DENV cross-reactive Abs (6). PBMCs were isolated (3), cry-
opreserved, and stored in liquid nitrogen until usage. DENV seropositivity
was determined by DENV IgG or an inhibition ELISA (7, 8).
IFN-g capture assay, sorting, and flow cytometry
Cells were stimulated with ZIKV peptide pools (4). Additionally, we used 309
ZIKV 9-mers and 10-mers corresponding to previously identified epitopes
supplemented with predicted epitopes based on a 27-allele method (9) using
TepiTool, available in the Immune Epitope Database and Analysis Resource
(www.IEDB.org) (10). IFN-g–producing cells were captured using a cytokine
secretion assay (Miltenyi Biotech, Bergisch Gladbach, Germany) (11). Sorting
gating strategy is shown in Supplemental Fig. 1. For the intracellular cytokine
staining, PBMCs were cultured 6 h with 1 mg/ml peptide pools and BD
GolgiPlug (BD Biosciences, San Diego, CA), then permeabilized, stained,
and analyzed using FlowJo software (4). Supplemental Table II shows the Abs
used for sorting and flow cytometry experiments.
RNA sequencing, bioinformatics, and statistical data analysis
Two hundred cells for each condition were collected. To generate full-length
transcriptomes from the low cells per sample, we adapted the Smart-Seq2
protocol (12). Bioinformatics analysis to obtain the raw counts and dif-
ferentially expressed genes were performed as previously described (13). We
considered genes to be differentially expressed with an adjusted p value of
,0.05 and the log2 fold change in gene expression .1. Only genes with an
average transcript per million (TPM) count $10 in ZIKV IFN-g+ condi-
tion have been considered for further analysis. Principal component analysis
(PCA) was performed on the top 500 most variable genes using versust
transformation and the “prcomp” function in R, setting “scale” equal to
TRUE. The heatmap was generated on versust-transforming data using
Qlucore. Statistical analyses for FACS experiments were performed using
Prism 7 (GraphPad Software, San Diego, CA). One-tailed Mann–Whitney
or Wilcoxon tests were applied when appropriate. The data have been de-
posited in the Gene Expression Omnibus (GSE105884, http://www.ncbi.
nlm.nih.gov/geo/) and ImmPort (SDY903, http://www.immport.org).
Results and Discussion
To examine the nature of CD8+ T cell responses recognizing
ZIKV epitopes, we performed a transcriptomic analysis of
PBMCs from ZIKV-infected donors collected at the con-
valescent phase. In this study, PBMCs were stimulated ex
vivo with ZIKV-specific peptide pools, and Ag-specific
CD8+ T cells were sorted based on their ability to pro-
duce IFN-g. The patients’ CD8+ T cells that did not pro-
duce IFN-g in response to epitope stimulation from these
same cultures as well as total unstimulated CD8+ T cells
were also collected for comparison with their ZIKV-specific
IFN-g–producing CD8+ T cells. After sorting, microscaled
RNA sequence determinations were performed on low cell
numbers (12). We then analyzed the global gene expression
patterns using PCA of the 500 most variable genes ob-
tained after RNA sequencing (Fig. 1A). Unstimulated and
ZIKV-stimulated IFN-g2 CD8+ T cells clustered together
and were clearly separated from the gene expression profiles
of the ZIKV-stimulated IFN-g+ CD8+ T cells. This sug-
gested that the main component of human CD8+ T cell
response to ZIKV epitopes were from their IFN-g– producing
cells, in agreement with previous studies on both ZIKV and
the closely related DENV regarding CD8 responses (1, 3, 4,
14, 15). The IFN-g2 CD8+ T cells may also include some, if
not many, ZIKV-specific T cells, which did not secrete
IFN-g but instead secreted IL-2 or TNF-a under the
stimulation of peptides. Further experiments targeting cell
subpopulations secreting other cytokines or selected on the
basis of specific activation markers could be performed in the
future to broaden the characterization of ZIKV-specific
CD8+ T cell responses.
The interplay between ZIKV and DENV is an important
issue because ZIKV and DENV not only share a high level of
protein sequence homology but are also transmitted by the
same mosquitoes, and ZIKV transmission has predominantly
occurred in DENV-endemic areas (16). We have previously
shown that prior DENV exposure modulates ZIKV responses
when comparing acute samples that were DENV naive or
previously exposed (4). In this study, we do not observe dif-
ferences both in terms of frequency of IFN-g+ cells of DENV
seronegative and seropositive (Supplemental Fig. 1B) as well
as in terms of gene expression observed (Fig. 1A), suggesting
that DENV pre-exposure might affect ZIKV CD8+ T cells
only during the acute phase of the infection. These prelimi-
nary findings should be further explored; however, they are in
agreement with previous work in which small differences in
monocyte gene expression profiles were observed in patients
who had ZIKV or DENV infections, suggesting similari-
ties between the two viral infections at the gene expression
level (17).
To identify gene expression patterns associated with ZIKV-
specific CD8+ T cell responses, we determined the differential
gene expression profiles of the patients’ IFN-g2 and IFN-g+
cells after ZIKV peptide pools stimulation and on IFN-g2 cells
that were unstimulated or stimulated with ZIKV (Fig. 1B).
Overall, a total of 153 genes were differentially expressed in
either one of these two analyses. Of these, 142 genes were
upregulated at least 2-fold in the IFN-g+ compared with the
IFN-g2 ZIKV-stimulated cells, and 32 genes were differentially
upregulated at a more stringent cutoff of a 4-fold level in
IFN-g+ compared with IFN-g2 cells (Fig. 1C). These results
further emphasize that the main component of CD8+ responses
to ZIKV peptides were the IFN-g–producing cells (4).
Next, we more closely inspected the mRNA sequence
profiles of the IFN-g+ CD8+ T cells to ascertain which genes
at a more stringent 4-fold change cutoff were upregulated in
the ZIKV-specific CD8+ T cells (Fig. 1C). Interestingly,
among the most significantly upregulated genes were those
encoding granzyme B (GZMB) and cytotoxic and regulatory
T cell molecule (CRTAM), implying that the CD8 responses
were not limited to cytokine release but were also associated
with the hallmarks of a cytotoxic response (18). Among the
other strongly upregulated genes were those associated with
cellular activation, such as tumor necrosis receptor super-
family member 9 (TNFRSF9), which encodes the CD137
protein (also known as 4-1BB), important in priming and
promoting CD8+ T cell effector and memory functions in the
context of viral infection (19), and CD69, which encodes an
important marker of T cell activation. In addition, significant
upregulation was also noted for NFKBID, which encodes an
NF known to be involved in homeostasis of the immune
system that is activated after TCR stimulation (20). Other
upregulated genes that correlated with activation were TNF
ligand superfamily member 6/Fas ligand gene (TNFL6/
FASLG) and member 14 (TNFSF14/CD258), which encode
proteins involved in cytotoxic T cell apoptotic processes and
immune regulation, and ERG2, encoding an upstream regu-
lator of effector CD4+ and CD8+ T cells linked with pro-
tective responses and limiting immunopathology (21) as well
as with regulating CD8+ T cell activation (22).
Other prominently upregulated genes were X-C motif
chemokine ligand 1 and 2 (XCL1 and XCL2), which encode
chemokines with inflammatory function that are known to
induce leukocyte migration and activation (23). The genes
encoding the chemokine (C-C motif) ligand 3 and 4 (CCL3
and CCL4) proteins, associated with inflammation and in the
case of CCL3 also with CD8 effector function, were also
upregulated (24).
Based on the gene function described above and available in
UniProt knowledgebase database (https://www.uniprot.org/),
we functionally grouped together the genes more strongly
upregulated in ZIKV-specific CD8+ T cell genes into five
main groups: 1) polyfunctional cytokines, 2) cytotoxicity, 3)
T cell activation and regulation, 4) proinflammation, and 5)
T cell homing.
We previously reported, using a different cohort of donors/
samples, that ZIKV-specific CD8+ T cell responses were
characterized by IFN-g, TNF-a, and GZMB release (4). We
then compared the geometric mean of fluorescence intensity
expression of IFN-g, TNF-a, and GZMB in IFN-g2 and
IFN-g+ cell groups, reanalyzing our previously published data
(4) (Supplemental Fig. 2B, 2D, 2F), to the TPM count
originated by the mRNA sequence determinations performed
in the current study. All genes (IFN-g, TNF-a, and GZMB)
encoding the proteins found to be upregulated by FACS
analysis in previous studies were also found to be upregulated
at the mRNA level in this study (Supplemental Fig. 2C, 2E,
2G). To further validate the CD8+ T cell ZIKV signature
obtained by the mRNA sequence determinations and analy-
ses, we selected six additional proteins (CD137, CD258,
FASLG, CCL3, CRTAM, and CD69) based on differential
expression of their corresponding genes (changes of .4-fold,
p-adjusted values ,0.05) (Fig. 1C) and the availability of a
suitable commercial mAb to detect them. The protein-level
expression of these markers was determined on a set of
12 donors known to respond to stimulation with ZIKV
peptides, as previously reported (4), after a 6-h stimulation
period with ZIKV-specific pooled peptides and intracellular
staining. Overall, there was a good correlation between
FIGURE 1. Gene expression analysis of ZIKV-specific CD8+ T cells. (A) PCA of unstimulated IFN-g2 (gray) and ZIKV-stimulated IFN-g2 (black) and IFN-
g+ (red). DENV pre-exposed (circles) and DENV naive (square) are also shown (B). Heatmap of differentially expressed genes after comparison of IFN-g2 and
IFN-g+ cells stimulated with ZIKV pools. (C) Differentially expressed genes based on adjusted p value and log2 fold change gene expression. Genes with log2 fold
change .2 are highlighted.
upregulation at the mRNA (Fig. 2A) and protein (Fig. 2B)
expression levels. Our results demonstrated that the CD8+
T cell responses recognizing ZIKV-specific epitopes were
prevalently associated with IFN-g+ cells, as expected from our
experimental strategy, and that this response appeared to be
fully functional, as demonstrated by the upregulation of genes
involved in cytotoxicity, chemotaxis, and inflammation. To
prove that these observations were generally applicable re-
gardless of the particular cohort analyzed or the time elapsed
postinfection, we also analyzed the same markers on PBMCs
from a different cohort in Barranquilla (Colombia) that had
been collected 1–2 y after ZIKV infection. This independent
ZIKV cohort showed patterns of protein upregulation re-
markably similar to those detected in the previous cohort
(Fig. 2C). These data, therefore, demonstrated that this ex-
pression signature was both reproducible and temporally
stable after Ag-specific stimulation even 1–2 y after ZIKV
infection. In summary, we report, to our knowledge, the
first human immune profile of CD8+ T cells after ZIKV
Ag-specific stimulation. Our data show that ZIKV-specific
CD8+ T cell responses were predominantly associated with
IFN-g responses and that their gene expression signatures
were further associated with cytokine polyfunctionality and
cytotoxic activity. These common features were independent
of DENV pre-exposure, geographical location, or time of
sample collection postinfection and were identified both at
the mRNA and protein level, therefore making these suitable
candidates to be evaluated in cellular vaccine-induced im-
mune responses. Because of the small volume of samples
available, we focused our study on immune profiling of
ZIKV-specific CD8+T cells. Future studies will address the
immune profiles of human ZIKV–specific CD4+ T cells and
compare the functionalities of CD4+ T cells with the ones of
CD8+ T cells. Indeed, recent studies in humans and mouse
models have shown the importance of ZIKV-specific CD4+
T cells in protecting from severe ZIKV severe and Ab de-
velopment (25–27). Additionally, it would be of interest to
test whether disease severity during the acute phase impacts
the gene transcription and protein expression in ZIKV-
specific T cells. However, the cohorts studied in this study
were mostly characterized by a mild form of ZIKV disease
and, therefore, this analysis could not be performed based on
FIGURE 2. Correlation of expression at the mRNA and protein levels in CD8+ T cells of selected markers. (A) TPM for CD137, CD258, FASLG, CCL3,
CRTAM, and CD69 genes. (B and C) Geometric mean of fluorescence intensity for intracellular protein level determinations (B). ZIKV-independent cohort
collected 1–2 y postinfection (C). *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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the current cohort. In conclusion, the current study represents 
a baseline for comparison between different clinical outcomes 
of ZIKV infection in the CD8+ T cell context.
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3047 Puerto Rico RNA sequencing 90 convalescent pos not severe
3052 Puerto Rico RNA sequencing 90 convalescent pos not severe
3028 US travellers RNA sequencing 24 convalescent pos not determined
3031 US travellers RNA sequencing 45 convalescent pos not determined
2653 US travellers RNA sequencing 365 convalescent neg not severe
3030 US travellers RNA sequencing 60 convalescent neg not determined
3053 Puerto Rico RNA sequencing 90 convalescent neg not severe
3054 Puerto Rico RNA sequencing 90 convalescent neg not severe
3027 US travellers RNA sequencing /validation 150 convalescent pos not determined
3038 Puerto Rico RNA sequencing /validation 90 convalescent pos not severe
3037 Puerto Rico RNA sequencing /validation 90 convalescent pos not severe
3045 Puerto Rico RNA sequencing /validation 90 convalescent pos not severe
2894 US travellers RNA sequencing /validation 90 convalescent neg not severe
3126 Puerto Rico validation 90 convalescent pos not severe
3127 Puerto Rico validation 90 convalescent pos not severe
3128 Puerto Rico validation 90 convalescent pos not severe
3129 Puerto Rico validation 90 convalescent pos not severe
3130 Puerto Rico validation 90 convalescent pos not severe
3131 Puerto Rico validation 90 convalescent pos not severe
3132 Puerto Rico validation 90 convalescent pos not severe
3421 Colombia validation 475 convalescent pos Guillain-Barré Syndrome
3422 Colombia validation 565 convalescent pos Guillain-Barré Syndrome
3423 Colombia validation 565 convalescent pos not severe
3424 Colombia validation 505 convalescent pos not severe
3428 Colombia validation 535 convalescent pos Guillain-Barré Syndrome
3430 Colombia validation 595 convalescent pos not severe
a) Previous exposure to DENV (Positive or Negative) was determined by the presence of detectable DENV-specific IgG titers.1 
2 
Supplementary Table S1. List of ZIKV positive donors in convalescent phase, confirmed either by RT-3 
PCR and/or ZIKV serology after serum depletion. 4 
Target Color Vendor Clone species reactivity Experiment
CD14 V500 BD Biosciences M5E2 mouse human Sorting/Flow cytometry
CD19 V500 BD Biosciences HIB19 mouse human Sorting/Flow cytometry
Live/Dead ef506 eBioscience Sorting/Flow cytometry
CD3 AF700 eBioscience UCHT1 mouse human Sorting/Flow cytometry
CCR7 PerCP Cy5.5 Biolegend G043H7 mouse human Sorting
CD45RA ef450 eBioscience HI100 mouse human Sorting
CD8 BV650 BioLegend RPA-T8 mouse human Sorting/Flow cytometry
CD4 APCef780 eBioscience RPA-T4 mouse human Sorting/Flow cytometry
APC-CY7 BioLegend 4S.B3 Mouse human Flow cytometry
CD69 PE Cy7 eBioscience FN50 Mouse human Flow cytometry
CD137 (4-1BB) APC BioLegend 4B4-1 Mouse human Flow cytometry
CD355 (CRTAM) PE/Cy7 ebioscience Cr24.1 Mouse human Flow cytometry
CD178 (Fas-L) PE Biolegend NOK-1 Mouse human Flow cytometry
CD258 (LIGHT) AF647 BD Biosciences 115520 Mouse human Flow cytometry
CCL3 PE ebioscience CR3M Mouse human Flow cytometry
1 
Supplementary Table S2. List of monoclonal antibody used for Sorting and Flow cytometry validation 2 
experiments.3 
